RMD Open

Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis

Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in ...
rmdopen.bmj

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review

Methods Searches included MEDLINE, EMBASE and PubMed. Evaluations of diagnostic accuracy of imaging tests for PMR were eligible, excluding reports with <10 PMR cases. Two authors independently ...
rmdopen.bmj

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry

Objectives To assess the effectiveness of switching biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with low-inflammatory difficult-to-treat rheumatoid ...
rmdopen.bmj

Distinct clinical outcomes based on multiple serum cytokine and chemokine profiles rather than autoantibody profiles and ultrasound findings in rheumatoid arthritis: a ...

Objectives To evaluate the potential of clinical factors, ultrasound findings, serum autoantibodies, and serum cytokine and chemokine profiles as predictors of clinical outcomes in rheumatoid ...
rmdopen.bmj

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index

Objectives To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease ...
rmdopen.bmj

Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis

Objective The aim of this study was to investigate the relationship between antineutrophil cytoplasmic antibodies (ANCA) specificity and the risk of major adverse cardiovascular events (MACE) in ...
rmdopen.bmj

Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis

The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience persistent disease activity, leading to the concept of ‘difficult-to-treat ...
rmdopen.bmj

Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data

Objective Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the ...
rmdopen.bmj

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study

Objectives This prespecified interim analysis of the PRO-SPIRIT observational study compares the effectiveness and persistence of ixekizumab (IXE) with other biologic or targeted synthetic ...
rmdopen.bmj

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using ...
rmdopen.bmj

Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide

Background This study evaluated the efficacy and safety of avacopan versus a prednisone taper in the subgroup of patients with antineutrophil cytoplasmic antibody-associated vasculitis (granulomatosis ...